Elite Pharmaceuticals, Inc. (QB) Stock Price - ELTP

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Ultimate Trader
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
Elite Pharmaceuticals, Inc. (QB) ELTP OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.0021 -2.36% 0.0869 0.0885 0.0838 0.0885 0.089 16:00:06
Bid Price Ask Price Spread Spread % News
0.0838 0.09 0.0062 6.89% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
28 181,900 $ 0.085613 $ 15,573 859,383 0.0333 - 0.141
Last Trade Time Type Quantity Stock Price Currency
15:46:14 30,000 $ 0.0869 USD

Elite Pharmaceuticals, Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 72.37M 832.84M $ -3.67M - - 793.80M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
300.00 $ - 0.00% - -

more financials information »

Elite Pharmaceuticals, Inc. (QB) News

Loading Messages....

Latest ELTP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ELTP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.10150.1050.080.08864931,088,600-0.0146-14.38%
1 Month0.07560.1050.07510.087559676,9130.011314.95%
3 Months0.063750.1410.060.095248912,0150.0231536.31%
6 Months0.080.1410.03330.0754959837,3410.00698.63%
1 Year0.0780.1410.03330.0803975715,7380.008911.41%
3 Years0.1420.24950.03330.1128389827,702-0.0551-38.8%
5 Years0.27010.4430.03330.19301941,049,550-0.1832-67.83%

Elite Pharmaceuticals, Inc. (QB) Description

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic products which have been licensed to TAGI Pharma, Glenmark Pharmaceuticals, Inc., USA., and Lannett Company, Inc. Elite currently has twelve approved generic products, four generic products filed with the FDA, one approved generic products pending manufacturing site transfer, and an NDA filed for SequestOx. Elite's pipeline products include abuse-deterrent opioids which utilize the Company's patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.